logo
#

Latest news with #Enclave

Buick's Lineup is Aging, and It Doesn't Look Like That Will Change Anytime Soon
Buick's Lineup is Aging, and It Doesn't Look Like That Will Change Anytime Soon

Auto Blog

time6 days ago

  • Automotive
  • Auto Blog

Buick's Lineup is Aging, and It Doesn't Look Like That Will Change Anytime Soon

By signing up I agree to the Terms of Use and acknowledge that I have read the Privacy Policy . You may unsubscribe from email communication at anytime. View post: The Volvo EX90's Software Is So Bad That One Owner Is Taking Volvo To Court Buick is a big deal in China, but the General Motors brand is nowhere near as popular in the U.S. as it once was. That said, the automaker has seen modest success in 2025, with an almost 20-percent increase in sales in the second quarter and almost 30 percent so far this year. To continue building on that success, Buick is expected to make some changes to its catalog in the coming years, including cutting one of its more popular models, according to Automotive News. 0:07 / 0:09 VW will introduce a sub-$20,000 EV, but probably not here Watch More Buick currently imports the Envision from China, putting it in a challenging position with recent tariff changes, with up to a 45-percent charge on each SUV entering the country. Despite that, rumors suggest that Buick could update the Envision for 2026. Source: GM If Buick were to cut the Envision due to tariffs, it would slim its already tiny lineup to three models, leaving the Envista, Encore GX, and Enclave. The Enclave just received a complete redesign for the 2025 model year and is expected to receive a midcycle refresh for the 2028 model year. The Encore GX is expected to last until around 2029 before an update, and the Envista is relatively new, having only debuted for the 2024 model year in North America. A new EV is expected from the brand by 2029, leaving it without a fresh model for several years. We don't know much about the new model, but it's expected to arrive as a subcompact crossover similar in size to the new Chevrolet Bolt. While the brand offers EVs in other markets, it hasn't been as aggressive with electrification in the U.S., and its parent company, GM, has backed off its most forward-looking EV plans in favor of more affordable vehicles. Autoblog Newsletter Autoblog brings you car news; expert reviews and exciting pictures and video. Research and compare vehicles, too. Sign up or sign in with Google Facebook Microsoft Apple By signing up I agree to the Terms of Use and acknowledge that I have read the Privacy Policy . You may unsubscribe from email communication at anytime. 2024 Buick Encore GX Sport Touring — Source: Buick Part of GM's transition involves moving pickup truck production to a factory previously dedicated to EVs, but the facility will continue building battery cells, and the automaker's Spring Hill, TN factory is slated to begin battery production in late 2027. About the Author Chris Teague View Profile

BIOVAXYS ANNOUNCES EXTENSION OF OFFERING CLOSING DATE
BIOVAXYS ANNOUNCES EXTENSION OF OFFERING CLOSING DATE

Cision Canada

time15-07-2025

  • Business
  • Cision Canada

BIOVAXYS ANNOUNCES EXTENSION OF OFFERING CLOSING DATE

VANCOUVER, BC, July 15, 2025 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (" BioVaxys" or the " Company") announces an extension of its previously announced brokered private placement LIFE financing (the " Offering") consisting of a minimum of 5,714,285 units of the Company (each, a " Unit") at a post-consolidation price of $0.35 per Unit for minimum gross proceeds of $2,000,000 and a maximum of 8,571,428 Units at a post-consolidation price of $0.35 per Unit for maximum gross proceeds of up to $3,000,000. Each Unit will consist of one (1) post-consolidation common share in the capital of the Company (each, a " Post-Consolidation Common Share") and one (1) Post-Consolidation Common Share purchase warrant (each, a " Post-Consolidation Warrant"). Each Post-Consolidation Warrant will entitle the holder thereof to purchase one Post-Consolidation Common Share at a post-consolidation price of $0.50 for a period of 36 months from the closing date of the Offering. The Company engaged Enclave Capital LLC (" Enclave"), D12 Capital Markets Inc. (" D12"), and D12's affiliate, Foundation Markets Inc., to act as agents (together the " Agents"). Upon successful closing of the Offering, Enclave will receive a cash fee equal to 8% of the total proceeds received by the Company from Enclave investors (the " Enclave Fee"). In addition to the Enclave Fee, the Company will pay Enclave a cash fee of $10,000. D12 will receive a cash commission equal to 8% of the gross proceeds committed to the Company from any party introduced by the D12 and its affiliate. Such payment shall be paid by the Company in equal share to D12 as per their direction. The Company intends to use the net proceeds raised from the Offering for research and development, general corporate purposes, and working capital. Closing of the Offering is anticipated to occur no later than 45 days after this news release. Closing of the Offering and payment of the Agents' fee are subject to the satisfaction of certain conditions, including, but not limited to, acceptance by the CSE. Subject to compliance with applicable regulatory requirements and in accordance with National Instrument 45-106 – Prospectus Exemptions (" NI 45-106"), the Units issuable under the Offering will be offered for sale to purchasers in all provinces and territories of Canada, except Quebec, pursuant to the listed issuer financing exemption (" LIFE") under Part 5A of NI 45-106. The securities to be issued pursuant to the sale of the Units under the Offering will not be subject to resale restrictions in accordance with applicable Canadian securities laws (the " CSE"). There is an amended offering document dated July 14, 2025, related to the Offering that can be accessed under the Company's profile at and on the Company's website at Prospective investors should read this offering document before making an investment decision. This news release does not constitute an offer to sell or a solicitation of an offer to buy of any securities in the United States, or in any jurisdiction in which such offer, solicitation or sale would be unlawful. The securities described herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the " U.S. Securities Act"), or any state securities laws, and may not be offered or sold within the United States except in compliance with the registration requirements of the U.S. Securities Act and applicable state securities laws or pursuant to available exemptions therefrom. The Company affirms that it intends to undertake a consolidation of the common shares of the Company (the " Common Shares") on the basis of ten (10) pre-consolidation Common Shares for one (1) post-consolidation Common Share (the " Consolidation"), which will occur simultaneously with the Offering. The Company currently has 293,425,203 Common Shares issued and outstanding, and it is anticipated that immediately following the Consolidation, excluding Common Shares to be issued in connection with this Offering, the Company will have approximately 29,342,520 Common Shares issued and outstanding, prior to rounding of fractional Common Shares. The exercise or conversion price of the Company's convertible securities and the number of Common Shares issuable thereunder will also be proportionately adjusted upon completion of the Consolidation. No fractional Common Shares will be issued as a result of the proposed Consolidation. Any fractional Common Shares resulting from the proposed Consolidation will be rounded up in the case of a fractional interest that is one-half (1/2) of a Common Share or greater, or rounded down in the case of a fractional interest that is less than one-half (1/2) of a Common Share, to the nearest whole number of Common Shares, and no cash consideration will be paid in respect of fractional Common Shares rounded down to the nearest whole Common Share. The Company will issue a subsequent news release in respect of the proposed Consolidation to announce the effective date of the Consolidation, the new CUSIP and ISIN for the post-Consolidation Common Shares, and any other relevant details, and file all necessary documentation with the CSE in respect of the proposed Consolidation. The post-Consolidation Common Shares will continue to trade on the CSE under the Company's existing name and trading symbol. The Consolidation remains subject to requisite approvals, including acceptance by the CSE. About BioVaxys Technology Corp. BioVaxys Technology Corp. ( a biopharmaceuticals company registered in British Columbia, Canada, is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX™ immune-educating technology platform and it's HapTenix© tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization for food allergy, and other immunological diseases. Through a differentiated mechanism of action, the DPX™ platform delivers instruction to the immune system to generate a specific, robust, and persistent immune response. The Company's clinical stage pipeline includes maveropepimut-S (MVP-S), based on the DPX™ platform, and in Phase IIB clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant Ovarian Cancer. MVP-S delivers antigenic peptides from survivin, a well-recognized cancer antigen commonly overexpressed in advanced cancers, and also delivers an innate immune activator and a universal CD4 T cell helper peptide. MVP-S has been well tolerated and has demonstrated defined clinical benefit in multiple cancer indications as well as the activation of a targeted and sustained, survivin-specific anti-tumor immune response. BioVaxys is also developing DPX™+SurMAGE, a dual-targeted immunotherapy combining antigenic peptides for both the survivin and MAGE-A9 cancer proteins to elicit immune responses to these two distinct cancer antigens simultaneously, DPX™-RSV for Respiratory Syncytial Virus, DPX+rPA for peanut allergy prophylaxis, and BVX-0918, a personalized immunotherapeutic vaccine using its proprietary HapTenix© 'neoantigen' tumor cell construct platform for refractive late-stage ovarian cancer. BioVaxys common shares are listed on the CSE under the stock symbol "BIOV" and trade on the Frankfurt Bourse (FRA: 5LB) and in the U.S. on the OTC Markets (OTCQB marketplace). For more information, visit and connect with us on X and LinkedIn. ON BEHALF OF THE BOARD Signed " James Passin" James Passin, Chief Executive Officer Phone: +1 740 358 0555 Cautionary Statements on Forward Looking Information This news release includes certain "forward-looking information" and "forward-looking statements" (collectively " forward-looking statements") within the meaning of applicable securities legislation. All statements, other than statements of historical fact, included herein, without limitation, statements relating to the future operating or financial performance of the Company, are forward-looking statements. Forward-looking statements are frequently, but not always, identified by words such as "expects", "anticipates", "believes", "intends", "estimates", "potential", "possible", and similar expressions, or statements that events, conditions, or results "will", "may", "could", or "should" occur or be achieved. Forward-looking statements in this news release relate to, among other things, the proposed Consolidation, including the ratio thereof and timing thereof, and the Offering, including the size and use of proceeds, and the timing and ability of the Company to close the Offering, including obtaining approval of the Offering from the CSE. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those expressed or implied in such forward-looking statements. Forward-looking statements reflect the beliefs, opinions and projections on the date the statements are made and are based upon a number of assumptions and estimates, primarily the assumption that BioVaxys will be successful in developing and testing vaccines, that, while considered reasonable by BioVaxys, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies including, primarily but without limitation, the risk that BioVaxys' vaccines will not prove to be effective and/ or will not receive the required regulatory approvals. With regards to BioVaxys' business, there are a number of risks that could affect the development of its biotechnology products, including, without limitation, the need for additional capital to fund clinical trials, its lack of operating history, uncertainty about whether its products will complete the long, complex and expensive clinical trial and regulatory approval process for approval of new drugs necessary for marketing approval, uncertainty about whether its autologous cell vaccine immunotherapy can be developed to produce safe and effective products and, if so, whether its vaccine products will be commercially accepted and profitable, the expenses, delays and uncertainties and complications typically encountered by development stage biopharmaceutical businesses, financial and development obligations under license arrangements in order to protect its rights to its products and technologies, obtaining and protecting new intellectual property rights and avoiding infringement to third parties and their dependence on manufacturing by third parties. Many factors, both known and unknown, could cause actual results, performance or achievements to be materially different from the results, performance or achievements that are or may be expressed or implied by such forward-looking statements and the parties have made assumptions and estimates based on or related to many of these factors. Such factors include, without limitation, the ability of the Company to complete the Consolidation and the Offering on the terms proposed or at all, and the ability to obtain necessary approvals, including the approval of the CSE. BioVaxys does not assume any obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by applicable securities laws.

GRAYA purchases 'once in a lifetime' Brisbane site for $20 million
GRAYA purchases 'once in a lifetime' Brisbane site for $20 million

7NEWS

time08-07-2025

  • Business
  • 7NEWS

GRAYA purchases 'once in a lifetime' Brisbane site for $20 million

Award-winning developer GRAYA has secured a rare Brisbane site, beating both local and overseas buyers in a competitive sale. "Sites like this are truly once in a lifetime," said director Rob Gray. "It's a rare opportunity to contribute to one of Australia's most iconic lifestyle destinations." The 943-square-metre site is located on James Street, a vibrant retail and hospitality destination in the heart of Brisbane's Fortitude Valley, and the current home of Bed Bath & Table. Speaking about the project, Gray said it will 'elevate' the iconic street's current offering. "We plan to deliver a world-class building that elevates the James Street experience - blending high-end food and beverage, luxury retail, and office spaces in a way that complements the area's unique culture," said Gray. The off-market sale was managed by Chesters Real Estate's head of sales Tim Jones, and colleagues Michael Platsis and Greer Gittoes. "James Street is without doubt among the most desirable retail and lifestyle precincts in the country," said Jones. "This benchmark transaction is a testament to the strength of the precinct, attracting high-calibre interest from investors, retailers, and developers alike. "GRAYA's plans will take it to the next level." While plans for the site have yet to be lodged, the team said in a statement that the project will be a landmark mixed-use precinct featuring a "design-led approach with a strong focus on curating an offering that enhances the precinct's lifestyle appeal and long-term commercial value." This isn't the only big news to come from the Brisbane-based developer though. The company has also recently lodged a development application for The Gallery, another project that promises to be a "bold new mixed-use precinct" aiming to "transform Hamilton's iconic Racecourse Road". The development will include 37 residences across four storeys, with eight retail tenancies. "There's long been a clear demand in Hamilton for a lifestyle precinct that combines luxury apartments with the type of vibrant, boutique retail we've seen delivered in places like James Street," says Gray. "The Gallery is our response to that demand. Hamilton has been a major part of our story for more than ten years - we know this community, so we're proud to be the ones bringing that vision to life." Brisbane-based architecture studio Bureau^Proberts will be leading the design, which is said to include a resident-only rooftop retreat, resort-style pool and panoramic views. A home to make you live longer Earlier this year, GRAYA announced its foray into the world of wellness with Enclave - a $140 million wellness tower that aims to help residents improve their health and maybe even their life expectancy. Integrating 'longevity science' into its design, the project includes an expansive spa and wellness centre that features treatments including IV drip therapy, massage, acupuncture and dry needling. "Enclave will cater to the growing global demand for holistic wellness and longevity, and will provide residents with services and equipment that you'd only find at the world's most exclusive wellness clubs," said Gray. The development will also include hot and cold plunge pools, a steam room and sauna, a hydrotherapy spa and mineral pools to indulge residents' every wellness need. Those who live in the exclusive development will also have access to a private gym, personal training, and advice from nutritionists and dieticians on site.

BIOVAXYS ENGAGES ENCLAVE CAPITAL LLC TO ACT AS AN AGENT IN BROKERED PRIVATE PLACEMENT OFFERING
BIOVAXYS ENGAGES ENCLAVE CAPITAL LLC TO ACT AS AN AGENT IN BROKERED PRIVATE PLACEMENT OFFERING

Cision Canada

time07-07-2025

  • Business
  • Cision Canada

BIOVAXYS ENGAGES ENCLAVE CAPITAL LLC TO ACT AS AN AGENT IN BROKERED PRIVATE PLACEMENT OFFERING

VANCOUVER, BC, July 7, 2025 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (" BioVaxys" or the " Company") announces it has engaged Enclave Capital LLC (" Enclave") to act as an agent, in collaboration with D12 Capital Markets Inc. and its affiliate, Foundation Markets Inc., in connection with the Company's previously announced brokered private placement LIFE financing (the " Offering"). Upon successful closing of the Offering, Enclave will receive a cash fee equal to 8% of the total proceeds received by the Company from Enclave investors (the " Offering Fee"). In addition to the Offering Fee, the Company will pay Enclave a cash fee of $10,000. All other terms and conditions of the Offering as previously announced on May 30, 2025, and amended on June 20, 2025, remain unchanged. Subject to compliance with applicable regulatory requirements and in accordance with National Instrument 45-106 – Prospectus Exemptions (" NI 45-106"), the units of the Company (each, a " Unit") issuable under the Offering will be offered for sale to purchasers in all provinces and territories of Canada, except Quebec, pursuant to the listed issuer financing exemption (" LIFE") under Part 5A of NI 45-106. The securities to be issued pursuant to the sale of the Units under the Offering will not be subject to resale restrictions in accordance with applicable Canadian securities laws. There is an amended offering document dated July 7, 2025, related to the Offering that can be accessed under the Company's profile at and on the Company's website at Prospective investors should read this offering document before making an investment decision. This news release does not constitute an offer to sell or a solicitation of an offer to buy of any securities in the United States, or in any jurisdiction in which such offer, solicitation or sale would be unlawful. The securities described herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the " U.S. Securities Act"), or any state securities laws, and may not be offered or sold within the United States except in compliance with the registration requirements of the U.S. Securities Act and applicable state securities laws or pursuant to available exemptions therefrom. About BioVaxys Technology Corp. BioVaxys Technology Corp. ( a biopharmaceuticals company registered in British Columbia, Canada, is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX™ immune-educating technology platform and it's HapTenix© tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization for food allergy, and other immunological diseases. Through a differentiated mechanism of action, the DPX™ platform delivers instruction to the immune system to generate a specific, robust, and persistent immune response. The Company's clinical stage pipeline includes maveropepimut-S (MVP-S), based on the DPX™ platform, and in Phase IIB clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant Ovarian Cancer. MVP-S delivers antigenic peptides from survivin, a well-recognized cancer antigen commonly overexpressed in advanced cancers, and also delivers an innate immune activator and a universal CD4 T cell helper peptide. MVP-S has been well tolerated and has demonstrated defined clinical benefit in multiple cancer indications as well as the activation of a targeted and sustained, survivin-specific anti-tumor immune response. BioVaxys is also developing DPX™+SurMAGE, a dual-targeted immunotherapy combining antigenic peptides for both the survivin and MAGE-A9 cancer proteins to elicit immune responses to these two distinct cancer antigens simultaneously, DPX™-RSV for Respiratory Syncytial Virus, DPX+rPA for peanut allergy prophylaxis, and BVX-0918, a personalized immunotherapeutic vaccine using its proprietary HapTenix© 'neoantigen' tumor cell construct platform for refractive late-stage ovarian cancer. BioVaxys common shares are listed on the CSE under the stock symbol "BIOV" and trade on the Frankfurt Bourse (FRA: 5LB) and in the U.S. on the OTC Markets (OTCQB marketplace). For more information, visit and connect with us on X and LinkedIn. ON BEHALF OF THE BOARD Signed " James Passin" James Passin, Chief Executive Officer Phone: +1 740 358 0555 Cautionary Statements on Forward Looking Information This news release includes certain "forward-looking information" and "forward-looking statements" (collectively " forward-looking statements") within the meaning of applicable securities legislation. All statements, other than statements of historical fact, included herein, without limitation, statements relating to the future operating or financial performance of the Company, are forward-looking statements. Forward-looking statements are frequently, but not always, identified by words such as "expects", "anticipates", "believes", "intends", "estimates", "potential", "possible", and similar expressions, or statements that events, conditions, or results "will", "may", "could", or "should" occur or be achieved. Forward-looking statements in this news release relate to, among other things, the terms and conditions of the Offering. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those expressed or implied in such forward-looking statements. Forward-looking statements reflect the beliefs, opinions and projections on the date the statements are made and are based upon a number of assumptions and estimates, primarily the assumption that BioVaxys will be successful in developing and testing vaccines, that, while considered reasonable by BioVaxys, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies including, primarily but without limitation, the risk that BioVaxys' vaccines will not prove to be effective and/ or will not receive the required regulatory approvals. With regards to BioVaxys' business, there are a number of risks that could affect the development of its biotechnology products, including, without limitation, the need for additional capital to fund clinical trials, its lack of operating history, uncertainty about whether its products will complete the long, complex and expensive clinical trial and regulatory approval process for approval of new drugs necessary for marketing approval, uncertainty about whether its autologous cell vaccine immunotherapy can be developed to produce safe and effective products and, if so, whether its vaccine products will be commercially accepted and profitable, the expenses, delays and uncertainties and complications typically encountered by development stage biopharmaceutical businesses, financial and development obligations under license arrangements in order to protect its rights to its products and technologies, obtaining and protecting new intellectual property rights and avoiding infringement to third parties and their dependence on manufacturing by third parties. Many factors, both known and unknown, could cause actual results, performance or achievements to be materially different from the results, performance or achievements that are or may be expressed or implied by such forward-looking statements and the parties have made assumptions and estimates based on or related to many of these factors. Such factors include, without limitation, the ability of the Company to complete the Offering, and the ability to obtain necessary approvals, including the approval of the Canadian Securities Exchange. BioVaxys does not assume any obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by applicable securities laws.

Wynn Al Marjan Island unveils ultra luxury offering at RAK
Wynn Al Marjan Island unveils ultra luxury offering at RAK

Zawya

time04-07-2025

  • Business
  • Zawya

Wynn Al Marjan Island unveils ultra luxury offering at RAK

UAE - Wynn Al Marjan Island, the UAE's first gaming resort coming up in Ras Al Khaimah, has unveiled the first look of its ultra luxury offering - Enclave - a new hallmark of Wynn's platinum-standard hospitality with bespoke service, extraordinary amenities, and lavish accommodations high above the grandeur of the greater Wynn Al Marjan Island resort. Created by Wynn Design & Development, Enclave will feature a collection of 313 residences - including six distinct layouts, ranging from Enclave King Suites starting at 75 sqm to two lavish, two-story Royal Apartments measuring 1,500 sqm. Conceived as a supremely elegant, coastal mansion of rarefied tranquility and anticipatory service, the arrival to Enclave occurs via a private, guarded, and verdant entry drive that welcomes guests into an exquisite lobby available exclusively to in-residence Enclave guests, said the developer. Designed as an exceptionally rarefied address, Enclave is defined by its exclusivity and intimacy, with an elevated focus on privacy and intuitive service within an opulent world unto itself. The lobby salons of Enclave are a prelude to a stunning processional gallery that leads guests to private elevators, which ascend to the hushed serenity of no more than 15 suites per floor. Located on the uppermost levels of the resort's iconic 300-meter tower, Enclave's accommodations are awash in a stunningly tranquil palette of platinum, sapphire, cream, gold, and sea mist, hues that float cloud-like above the crystal-clear waters of Wynn Al Marjan Island, it stated. True to Wynn's signature approach to creating spaces of timeless and enduring elegance, the suites envelop guests in a deeply residential sensibility and an aesthetic that embraces their stunning location in the sky, while also being deeply rooted in the lore of the region and its many international influences. Thoughtfully curated in-room amenities anticipate the expectations of discerning international travelers around the clock. Dual in-room private pantries reflect this commitment to anticipatory service and amenities: AM and PM provisions are presented in separate bespoke cabinetry and offer a refined product assortment tailored to each suite type. Wynn's anticipatory approach to exceeding the expectations of its global clientele is evident in every detail of the suites' design, with deep consideration given to important cultural sensitivities and preferences. Wynn Al Marjan Island will attract Wynn Resorts' most diverse and sophisticated international clientele, and the accommodations within Enclave reflect this in every detail. Unveiling the first look, Todd-Avery Lenahan, the President & Chief Creative Officer of Wynn Design & Development. said: "Wynn Resorts' passion for launching Enclave for the first time provided us the opportunity to deliver an experience unlike anything that exists in this region of the world: the challenge has been to build upon our expertise in creating intimacy within grandeur and to redefine the integrated resort experience." "With the imagining of Enclave, we've invested exceptional design sensitivity into the importance of personal scale and a heightened sense of individual recognition. Every dimension of our design process in creating this jewel within Wynn Al Marjan Island's crown has been as artful and precise as cutting and polishing the facets of a rare and priceless gem," he stated. "As with the overall resort's design concept of 'veiling and revealing' at every turn, it's often what's not seen that is more alluring and beautiful than what's obvious. That's what makes the rarefied veil of Enclave so special," he added. Positioned at the peak of the Wynn Tower, two Royal Apartments of unprecedented extravagance and scale will make their debut within Wynn Al Marjan's Enclave. As the penultimate commissions of internationally renowned designers Anouska Hempel (London) and Pinto Design (Paris) in collaboration with Wynn Design & Development, the Royal Apartments will be unrivaled by anything on the world stage of hospitality design and usher in a new era of Wynn's signature approach to creating experiences of celebrated elegance and glamour. Another hallmark of the Enclave experience is its private reserve pool and beach setting along the East edge of the resort's gardens, said Lenahan. Here, Enclave guests will enjoy a commanding view of Wynn Al Marjan Island's pristine shoreline and nightly sunsets in the Arabian Gulf's western sky. Designed to accommodate a variety of experiences, ranging from quiet, secluded retreat to fun family gatherings, three pools and a private beach are situated within a verdant tropical setting of chic cabanas and private bungalows. As a hallmark of the Enclave pool and garden experience, beach butlers offer dining service on-demand, with every need anticipated from the comfort of a guest's poolside chaise, cabana, or bungalow, he stated. Central to the Enclave experience is its restaurant located above the grand lobby, welcoming guests into a rich and luminous setting that is at once stylish and timeless. Breakfast service is offered exclusively to Enclave guests, after which the glittering skylit restaurant transforms for lunch and dinner into a vibrant celebration of Lebanese cuisine. The authenticity and artfulness of the cuisine will define the restaurant as a new culinary landmark, helmed by a renowned Beirut and Paris restaurateur whose UAE debut comes with the opening of Wynn Al Marjan Island's Enclave, he added. Slated to open in early 2027, the $3.9-billion Wynn Al Marjan Island will come up on a sprawling 60 hectares area. It comprises 1,217 resort rooms and 297 Enclave suites, plus two Royal Apartments, four garden Townhomes, and 10 Marina Estates. Additionally, guests will discover 24 international dining, lounges and club venues, the region's most opulent spa and beauty destination, it added.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store